Zai Lab to Present Early Phase 1 Data on Anti-CCR8 Antibody ZL-1218 at ESMO 2024

Zai Lab Limited has announced that data from a Phase 1 study of their anti-CCR8 antibody, ZL-1218, will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 scheduled for September 13-17, 2024, in Barcelona, Spain. The presentation will focus on preliminary results from an ongoing dose-escalation clinical trial, aiming to showcase the antibody's impact on regulatory T cells and its ability to modulate T-cell function within the tumor microenvironment of advanced solid tumors.

ZL-1218 is a humanized monoclonal antibody designed with an enhanced Fc region to target CCR8, a chemokine receptor primarily found on tumor-associated regulatory T cells (Treg). The antibody's mechanism includes depleting these CCR8+ Treg cells through antibody-dependent cellular cytotoxicity, which is anticipated to enhance the immune response against tumors. This innovative approach positions ZL-1218 as a potential therapeutic for treating various solid tumors.

The current Phase 1 study of ZL-1218 involves its use both as a standalone treatment and in combination with pembrolizumab in patients suffering from advanced solid tumor malignancies. The global trial is actively enrolling participants, reflecting the company's commitment to advancing its oncology pipeline.

Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab, emphasized the importance of overcoming the complexities of the tumor microenvironment to improve outcomes in cancer immunotherapy. He expressed optimism that ZL-1218's ability to reduce suppressive tumor-associated regulatory T cells could re-stimulate the immune system's attack on advanced solid tumors. Dr. Amado also mentioned that the company is eager to share the initial findings from their Phase 1 study at the ESMO 2024 congress.

The Zai Lab poster presentation at ESMO 2024 is titled "Preliminary Clinical PK and PD Analysis of a Phase 1 Study of ZL-1218, a Humanized Anti-CCR8 IgG1 Antibody, in Patients with Advanced Solid Tumors." The presentation, identified by the number 1008P, will be delivered by Oriol Mirallas, a Medical Oncology Specialist at the Vall d’Hebron Institute of Oncology in Barcelona. The session is scheduled for Saturday, September 14, 2024, at the Fira Barcelona Gran Via.

Zai Lab is a biopharmaceutical company with a focus on innovation, based in both China and the United States. The company is dedicated to discovering, developing, and commercializing products that address significant unmet medical needs in oncology, immunology, neuroscience, and infectious diseases. With a strong research and development foundation, Zai Lab aims to make a positive impact on global health.

The company's ongoing work with ZL-1218 and other compounds underscores its commitment to advancing cancer treatments and improving patient outcomes worldwide. The upcoming presentation at the ESMO Congress represents a significant milestone in the development of ZL-1218 and highlights Zai Lab's role in the global effort to combat cancer through innovative therapies.